Agree with Alterego, the projected revenue EBITDA and operating margin all look great and are on track to happen.
People were willing to pay $16 per share for this company. I have seen nothing to suggest the acceleration of product sales is going to decrease. Would still love for Laura and Rob to have updated the market on why they were selling a stake, we are all left to guess about their motivations. I think A2m and BAL are not on the same growth trajectory. Shorters definitely went after this, it's a volatile market but greed will takeover from fear soon enough then once the shorters start to lose control there will be the usual landslide. At least that's the plan
My impression is the shorters don't have any damning information and are simply feeding off the negative sentiment and got a boost from the ASX falling today too.
IMO It's a coiled spring not a collapsing pavlova people!
- Forums
- ASX - By Stock
- BAL
- Picking The Top
Picking The Top, page-339
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online